Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030550 · ClinicalTrials.gov registry record · Phase 2
Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00030550 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute.
The verdict
NCT00030550, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Thalidomide may be an effective treatment for anemia caused by myelodysplastic syndrome. PURPOSE: Randomized phase II trial to study the effectiveness of thalidomide in treating anemia in patients who have myelodysplastic syndrome.
Interventions
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030550
The ClinicalTrials.gov registry entry for NCT00030550 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which thalidomide is the first listed.
NCT00030550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00030550 about?
NCT00030550 is a clinical study titled "Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome". RATIONALE: Thalidomide may be an effective treatment for anemia caused by myelodysplastic syndrome. PURPOSE: Randomized phase II trial to study the effectiveness of thalidomide in treating anemia in patients who have myelodysplastic syndrome.
What is the current status of trial NCT00030550?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-09.
What interventions are being tested in trial NCT00030550?
The interventions under investigation include: thalidomide (DRUG).
Who is sponsoring clinical trial NCT00030550?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.